专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US09993487B2 Cyclodextrin and budesonide derivative compositions and methods 有权
公开(公告)号：US09993487B2
公开(公告)日：2018-06-12
申请号：US14672831
申请日：2015-03-30
申请人： Universite de Liege , Paul Maes
发明人： Didier Cataldo , Brigitte Evrard , Gilles Dufour , Pascal de Tullio , Paul Maes
IPC分类号： A61K31/58 , A61K31/56 , A61K31/573 , C08B37/16 , C08L5/16 , A61K9/00 , A61K31/57 , A61K47/40 , A61K47/69
CPC分类号： A61K31/58 , A61K9/0073 , A61K31/56 , A61K31/57 , A61K31/573 , A61K47/40 , A61K47/6951 , C08B37/0015 , C08L5/16
摘要： The present invention relates to novel and useful pharmaceutical compositions formulated with a cyclodextrin compound and a budesonide derivative for the treatment and/or prevention of pulmonary inflammatory disease. The present invention also relates to a novel and useful analytical technique for the detection and the quantification of HP-β-CD in solution. More specifically, the present invention relates to the use of a validated 1H NMR analysis for the detection and quantification of cyclodextrins directly in pharmaceutical formulations without any extraction or separation steps for liquid formulations.

2. 发明申请

US20160051568A1 CYCLODEXTRIN AND BUDESONIDE DERIVATIVE COMPOSITIONS AND METHODS 审中-公开
标题翻译：环糊精和布地奈德衍生物组合物和方法
公开(公告)号：US20160051568A1
公开(公告)日：2016-02-25
申请号：US14672831
申请日：2015-03-30
申请人： Paul Maes , Universite de Liege
发明人： Didier Cataldo , Brigitte Evrard , Gilles Dufour , Pascal de Tullio , Paul Maes
IPC分类号： A61K31/58 , A61K31/57 , A61K31/573 , A61K47/40 , A61K9/00
CPC分类号： A61K31/58 , A61K9/0073 , A61K31/56 , A61K31/57 , A61K31/573 , A61K47/40 , A61K47/6951 , C08B37/0015 , C08L5/16
摘要： The present invention relates to novel and useful pharmaceutical compositions formulated with a cyclodextrin compound and a budesonide derivative for the treatment and/or prevention of pulmonary inflammatory disease. The present invention also relates to a novel and useful analytical technique for the detection and the quantification of HP-β-CD in solution. More specifically, the present invention relates to the use of a validated 1H NMR analysis for the detection and quantification of cyclodextrins directly in pharmaceutical formulations without any extraction or separation steps for liquid formulations.
摘要翻译：本发明涉及用环糊精化合物和布地奈德衍生物配制的用于治疗和/或预防肺部炎性疾病的新型有用的药物组合物。本发明还涉及一种用于检测和定量溶液中HP-BGF-CD的新型和有用的分析技术。更具体地说，本发明涉及使用经验证的1H NMR分析来直接在药物制剂中检测和定量环糊精而不用任何用于液体制剂的提取或分离步骤。

3. 发明授权

US08932628B2 Modified release formulations of a bupropion salt 有权
公开(公告)号：US08932628B2
公开(公告)日：2015-01-13
申请号：US11762343
申请日：2007-06-13
申请人： Werner Oberegger , Fang Zhou , Paul Maes , Graham Jackson , Mohammad Ashty Saleh
发明人： Werner Oberegger , Fang Zhou , Paul Maes , Graham Jackson , Mohammad Ashty Saleh
IPC分类号： A61K9/48 , A61K31/135 , A61K31/137 , A61K9/20 , C07C225/16 , A61K9/28
CPC分类号： A61K9/0004 , A61K9/2027 , A61K9/28 , A61K9/2846 , A61K9/2866 , A61K9/2886 , A61K31/135 , A61K31/137 , C07B2200/13 , C07C225/16
摘要： The present invention relates to pharmaceutical compositions, formulations and medicaments comprising a bupropion salt, in particular, modified-release tablets comprising an effective amount of bupropion hydrobromide, and the use of the bupropion salt to prepare a medicament to treat a condition.

4. 发明申请

US20130266650A1 BUPROPION HYDROBROMIDE AND THERAPEUTIC APPLICATIONS 审中-公开
标题翻译：防腐剂和治疗应用
公开(公告)号：US20130266650A1
公开(公告)日：2013-10-10
申请号：US13752102
申请日：2013-01-28
申请人： Graham JACKSON , Werner Oberegger , Paul Maes , Mohammad Ashty Saleh
发明人： Graham JACKSON , Werner Oberegger , Paul Maes , Mohammad Ashty Saleh
IPC分类号： A61K31/137
CPC分类号： A61K31/137 , A61K9/2013 , A61K9/284 , A61K9/2846 , A61K9/2866 , A61K9/2886
摘要： Bupropion hydrobromide formulations as well as their use for the treatment of conditions is described.
摘要翻译：描述了安非他酮氢溴酸盐制剂及其用于治疗病症的用途。

5. 发明申请

US20090258067A1 MODIFIED RELEASE COMPOSITION OF AT LEAST ONE FORM OF VENLAFAXINE 审中-公开
标题翻译：至少一种芬替康的形式的改性释放组合物
公开(公告)号：US20090258067A1
公开(公告)日：2009-10-15
申请号：US12425819
申请日：2009-04-17
申请人： Fang ZHOU , Paul Maes , Steven Frisbee
发明人： Fang ZHOU , Paul Maes , Steven Frisbee
IPC分类号： A61K9/24 , A61K31/137
CPC分类号： A61K9/2018 , A61K9/2027 , A61K9/2054 , A61K9/284 , A61K9/2866
摘要： The present invention relates to a modified release composition of at least one form of venlafaxine, which is an enhanced absorption delayed controlled release composition. The composition comprises a core comprising at least one form of venlafaxine, less than 10% of a gelling agent and a pharmaceutically acceptable excipient. The composition further comprises a modified release coating which substantially surrounds the core which provides a delayed controlled release of the at least one form of venlafaxine.
摘要翻译：本发明涉及至少一种形式的文拉法辛的改进释放组合物，其是增强的吸收延迟控释组合物。组合物包含包含至少一种形式的文拉法辛，小于10％的胶凝剂和药学上可接受的赋形剂的核心。所述组合物还包含基本上围绕所述芯的改性释放涂层，其提供所述至少一种形式的文拉法辛的延迟控制释放。

6. 发明授权

US07348028B2 Chronotherapeutic diltiazem formulations and the administration thereof 失效
标题翻译：计时治疗性地尔硫卓制剂及其施用
公开(公告)号：US07348028B2
公开(公告)日：2008-03-25
申请号：US10657752
申请日：2003-09-09
申请人： Kenneth Stephen Albert , Theophilus Jones Gana , Paul Maes
发明人： Kenneth Stephen Albert , Theophilus Jones Gana , Paul Maes
IPC分类号： A61K9/14 , A61K9/16 , A61K9/20 , A61K9/22
CPC分类号： A61K31/55 , A61K9/2081 , A61K9/4866 , A61K9/5031 , A61K9/5047
摘要： A method of treating or preventing myocardial ischemia in a patient in need thereof comprising administration of a controlled-release Galenical preparation of pharmaceutically acceptable Diltiazem including the pharmaceutically acceptable salts thereof, suitable for evening dosing every 24 hours containing from about 180 mg to about 420 mg of the form of Diltiazem associated with excipients to provide controlled (sustained) release of the form of Diltiazem for providing a Cmax of Diltiazem in the blood at between about 10 hours and about 17 hours after administration, the preparation comprising the form of Diltiazem in oral sustained-release dosage form in which the Diltiazem is adapted to be released after administration over a prolonged period of time and exhibits when given to humans(i) a higher bioavailability when given at night compared to when given in the morning without food according to FDA guidelines or criteria and(ii) bioequivalence when given in the morning with and without food according to the same FDA guidelines or criteria.
摘要翻译：一种在有需要的患者中治疗或预防心肌缺血的方法，包括施用药学上可接受的地尔硫卓的可释放的Galenical制剂，包括其药学上可接受的盐，适合于每24小时进行晚间给药，其含有约180mg至约420mg 与给药相关的地尔硫卓形式，以提供受控（持续）释放的地尔硫卓形式，用于在给药后约10小时至约17小时之间在血液中提供地尔硫卓的最大值，包含地尔硫卓口服持续释放剂型形式的制剂，其中地尔硫卓适于在长时间给药后释放，并在给予人时显示（i）与给予时相比较，在晚上给予时具有较高的生物利用度在早晨没有食物根据FDA指导方针或标准，和（ii）生物等效性在早晨w给予根据相同的FDA指南或标准，不含食物。

7. 发明申请

US20070293584A1 MODIFIED RELEASE FORMULATIONS OF A BUPROPION SALT 有权
标题翻译：改良释放盐的配方
公开(公告)号：US20070293584A1
公开(公告)日：2007-12-20
申请号：US11766251
申请日：2007-06-21
申请人： Werner Oberegger , Fang Zhou , Paul Maes , Stefano Turchetta , Graham Jackson , Pietro Massardo , Mohammad Saleh
发明人： Werner Oberegger , Fang Zhou , Paul Maes , Stefano Turchetta , Graham Jackson , Pietro Massardo , Mohammad Saleh
IPC分类号： A61K31/12 , A61P25/24
CPC分类号： A61K9/0004 , A61K9/2027 , A61K9/28 , A61K9/2846 , A61K9/2866 , A61K9/2886 , A61K31/135 , A61K31/137 , C07B2200/13 , C07C225/16
摘要： The present invention relates to pharmaceutical compositions, formulations and medicaments comprising a bupropion salt, in particular, modified-release tablets comprising an effective amount of bupropion hydrobromide, and the use of the bupropion salt to prepare a medicament to treat a condition.
摘要翻译：本发明涉及包含安非他酮盐的药物组合物，制剂和药物，特别是包含有效量的安非他酮氢溴酸盐的改性释放片剂，以及使用安非他酮盐来制备治疗病症的药物。

8. 发明申请

US20050182056A9 Modified release formulations of at least one form of tramadol 审中-公开
标题翻译：至少一种曲马多的缓释制剂
公开(公告)号：US20050182056A9
公开(公告)日：2005-08-18
申请号：US10434266
申请日：2003-05-09
申请人： Seth Pawan , Paul Maes
发明人： Seth Pawan , Paul Maes
IPC分类号： A61K9/22 , A61K9/28 , A61K31/137 , A61K31/535 , A61K9/20
CPC分类号： A61K9/2866 , A61K9/284 , A61K31/137
摘要： The present invention provides for a modified release pharmaceutical composition comprising at least one form of tramadol selected from the group consisting of tramadol, enantiomers thereof, pharmaceutically acceptable salts thereof and combinations thereof, the composition exhibiting an in vitro dissolution profile (measured using the USP Basket Method at 75 rpm in 900 ml 0.1 N HCl at 37° C.) such that after 2 hours, from about 0% up to about 30% (by weight) of the at least one form of tramadol is released, after 4 hours, from about 5% to about 22% (by weight) of the at least one form of tramadol is released, after 6 hours, from about 15% to about 38% (by weight) of the at least one form of tramadol is released, after 8 hours, more than about 40% (by weight) of the at least one form of tramadol is released.
摘要翻译：本发明提供一种包含至少一种形式的曲马多的改性释放药物组合物，其选自曲马多，其对映异构体，其药学上可接受的盐及其组合，所述组合物显示体外溶出曲线（使用USP Basket 方法在75rpm，在900ml 0.1N HCl中于37℃下进行），使得在2小时后，释放至少一种形式的曲马多的约0％至约30％（重量），4小时后，释放约5％至约22％（重量）的该曲马多的至少一种形式的曲马朵，6小时后，至少一种曲马多的约15％至约38％（重量）被释放， 8小时后，释放至少一种形式的曲马多的大于约40％（重量）。

9. 发明授权

US5545628A Pharmaceutical composition containing fenofibrate 失效
标题翻译：含非诺贝特的药物组合物
公开(公告)号：US5545628A
公开(公告)日：1996-08-13
申请号：US370883
申请日：1995-01-10
申请人： Arthur Deboeck , Paul Maes , Phillipe R. Baudier
发明人： Arthur Deboeck , Paul Maes , Phillipe R. Baudier
IPC分类号： A61K47/14 , A61K9/48 , A61K31/195 , A61K31/216 , A61P3/06 , A01N43/04
CPC分类号： A61K9/4858 , A61K31/216 , A61K9/4866
摘要： A pharmaceutical composition is provided for treating hyperlipidemia or hypercholesterolemia or both in a mammal, which contains an effective amount of each of fenofibrate and an excipient containing one or more polyglycolyzed glycerides.
摘要翻译：提供了用于治疗哺乳动物的高脂血症或高胆固醇血症或两者的药物组合物，其含有有效量的非诺贝特和含有一种或多种聚乙二醇化甘油酯的赋形剂。

10. 外观设计

USD311134S Bottle 失效
公开(公告)号：USD311134S
公开(公告)日：1990-10-09
申请号：US857564
申请日：1986-04-22
申请人： Paul Maes
设计人： Paul Maes

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式